Tanya Dorff, MD, on New Findings on Talazoparib Monotherapy in Prostate Cancer

Posted: Thursday, September 1, 2022

Tanya Dorff, MD, of City of Hope, discusses findings from the TALAPRO-1 study, which explored the use of talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer with tumor DNA damage response alterations. In addition, Dr. Dorff examines the germline alteration landscape and potential associations with antitumor activity.